Biparametric MRI (bpMRI) and multiparametric MRI (mpMRI) differ primarily in the number of imaging sequences used: bpMRI includes only T2-weighted and diffusion-weighted imaging, while mpMRI adds dynamic contrast-enhanced (DCE) imaging.
mpMRI uses three sequences—T2-weighted, diffusion-weighted, and DCE—which requires intravenous gadolinium contrast.
This adds scan time, typically 30–40 minutes, with increased cost, and the need for a physician to be present for contrast administration, and carries risks such as allergic reactions and gadolinium deposition in tissues.
DCE is thought to aid in local staging and assessment of anatomical involvement, but its incremental value for cancer detection is debated.
bpMRI omits the DCE sequence, reducing scan time to 15–20 minutes, cost, and resource requirements, and eliminates contrast-related risks.
Recent high-quality studies and meta-analyses show that bpMRI is noninferior to mpMRI for detecting clinically significant prostate cancer, with similar sensitivity and specificity, and may even result in fewer false positives.
The PRIME trial and other multicenter studies confirm that bpMRI detects as much clinically significant cancer as mpMRI, without increasing detection of insignificant cancer or biopsy rates.
T2-weighted imaging- provides anatomical detail
Diffusion-weighted imaging (DWI)- shows how water molecules move through tissue.
Dynamic contrast-enhanced (DCE) imaging- requires intravenous gadolinium contrast injection to show blood flow patterns
mpMRI has been the standard protocol, offering detailed tissue characterization.
Biparametric MRI (bpMRI)
This simplified approach includes only:
T2-weighted imaging
Diffusion-weighted imaging (DWI)
It omits the DCE/contrast component.
Key Advantages of bpMRI
No contrast needed- eliminates risks associated with gadolinium (kidney concerns, rare allergic reactions)
Faster- typically 15-20 minutes vs 30-40 minutes
Lower cost-no contrast agent or IV placement needed
Better tolerated
Recent research suggests bpMRI performs similarly to mpMRI for:
Detecting clinically significant prostate cancer PI-RADS scoring (prostate imaging reporting system) Guiding biopsies
The DCE component adds relatively limited additional information in most cases, particularly for peripheral zone lesions.